Biomedical Engineering Reference
In-Depth Information
and association (e.g., AMA) reports and materials, (3) federal sources (e.g., FDA),
and (4) scientifi c journal articles, books, and editorials. This supplementary evi-
dence is also summarized in Table
24.1
.
References
AAMC (2008) Report of the AAMC Task Force on industry funding of medical education to the
AAMC Executive Council. Association of American Medical Colleges, Washington DC
Abelson R (2006) New nerve test, a moneymaker, divides doctors.
http://nytimes.com/2006/10/20/
snytandemc=rss&_r=0
. Accessed Oct 1, 2007
Ahearne M, Gruen T, Jarvis CB (1999) If looks could sell: moderation and mediation of the attrac-
tiveness effect of salesperson performance. Int J Res Market 16(4):269-284
Angell M (2005) The truth about the drug companies: how they deceive us and what to do about
it. Random House, New York
Angell M (2008) Industry sponsored clinical research: a broken system. J Am Med Assoc
300(9):1069-1071
Angelmar R (2005) Big Pharma: in need of treatment?” INSEAD Working Paper, 1-4.
Antonuccio D, Danton WG, McClanahan TM (2003) Psychology in the prescription era: building
a fi rewall between marketing and science. Am Psychol 58(12):1028-1043
Arrow KJ (1985) The economics of agency. In: Pratt JW, Zeckhauser RH (eds) Principals and
agents: the structure of business. Harvard Business School Press, Boston, pp 37-51
Arthur MM (2003) Share price reactions to work-family initiatives: an institutional perspective.
Acad Manage J 46(4):497-505
Bansal P, Clelland I (2004) Talking trash: legitimacy, impression management, and unsystematic
risk in the context of the natural environment. Acad Manage J 47(1):93-103
Barney JB, Hansen MH (1994) Trustworthiness as a source of competitive advantage. Strat
Manage J 15(Special Issue):175-190
Berenson A (2006) In the money, and in court. New York Times, April 22, C1
Bergstrom CT, Lachmann M (2003) The Red King effect: when the slowest runner wins the coevo-
lutionary race. Proc Natl Acad Sci 100(2):593-598
Boatright JR (1992) Confl icts of interest: an agency analysis. In: Bowie NE, Freeman RE (eds)
Ethics and agency theory. Oxford University Press, New York, pp 187-203
Bowman MA, Pearle DL (1988) Changes in drug prescribing patterns related to commercial com-
pany funding of continuing medical education. J Contin Educ Health Prof 8(1):13-20
Brennan TA, Mello MM (2007) Sunshine laws and the pharmaceutical industry. J Am Med Assoc
297(11):1255-1257
Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer
JP, Kimball H, Naughton J, Smelser N (2006) Health industry practices that create confl icts of
interest. J Am Med Assoc 295(4):429-433
Campbell EG, Weissman JS, Rao SR, Moy B, Feibelmann S, Goold SD (2007) Institutional
academic-industry relationships. J Am Med Assoc 298(15):1779-1786
Carlat D (2006) Generic smear campaign.
http://nytimes.com/2006/05/09/opinion/09carlat.html
(May 9). Accessed July 19, 2007
Caronna C (2004) The misalignment of institutional "pillars": consequences for the U.S. health
care fi eld. J Health Soc Behav 45(Suppl):45-58
Carreyrou J (2006) Cephalon used improper tactics to sell drug, probe fi nds. Wall Street Journal,
B1, Nov 21
Carson TL (2004) Confl icts of interest and self-dealing in the professions: a review essay. Bus
Ethics Q 14:161-182
Search WWH ::
Custom Search